Bausch Health Reports Results from the P-II Trial of Amiselimod for the Treatment of Ulcerative Colitis
Shots:
- The 12wks. P-II dose escalation trial assessed the safety and efficacy of amiselimod vs PBO for the treatment of mildly-to-moderately active ulcerative colitis (UC) patients (n=320)
- The results revealed that the mean change in modified Mayo Score at day 85 was -2.3 vs -1.6, clinical remission was 32.4% vs 17.8% and 42.7% vs 23.4% of patients attained endoscopic improvement (Mayo endoscopy subscore of ≤1)
- The safety results demonstrated that amiselimod had good tolerability, without unexpected AEs thus indicating a favorable safety profile. The complete data set is anticipated early next year
Ref: Bausch Health | Image: Bausch Health
Related News:- Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
